This project involved determination of the physicochemical properties of amino acid residues in dermorphins and deltorphins, environmentally derived from amphibian skin secretions; they exhibit high affinity and selectivity for endogenous mammalian opioid receptors. Applying solid and solution phase peptide chemistry, over 200 synthetic analogues were prepared using natural and unusual amino acids. Receptor studies with membranes from rat brain were statistically analyzed for 1- and 2-site binding models by a stringent iterative mode: fits to 2-site models included Hill coefficient < 0.85, narrow log of the 95% confidence interval (? 0.1), P < 0.0001. Importance of the side-chain and chirality of the residues in the N-terminal tetrapeptide region were identified and analyzed: e.g. Aib, Ala, or a series of 1-aminocycloalkane-1-carboxylic acids in positions 2 through 4 revealed that in the heptapeptide, the crucial D-amino acid isomer at position 2 and the critical aromatic side-chain at position 3 could be eliminated by hydrophobic residues. Substitutions of the anionic group by Pro or Abu indicated that the negative charge played a major role in delta receptor affinity, although delta selectivity was dependent on its presence. The acquisition of 5 affinity in some deltorphin analogues, comparable to dermorphin, conferred dual affinity in a single peptide. Based on these culmulative data, we developed a series of di- and tripeptide ultraselective opioidmimetic peptides that represent the universal opioid antagonist message and whose selectivity exceeded that of any known opioid by orders of magnitude. Investigations will continue to develop novel peptide analagues: agonists with potential application for chronic and acute pain, and antagonists to treat narcotic addiction, alcoholism and other clinical syndromes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES090053-08
Application #
5202279
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Lazarus, Lawrence H; Okada, Yoshio (2012) Engineering endomorphin drugs: state of the art. Expert Opin Ther Pat 22:1-14
Marczak, Ewa D; Jinsmaa, Yunden; Myers, Page H et al. (2009) Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol 616:115-21
Kang, Xuezhi; Chao, Dongman; Gu, Quanbao et al. (2009) delta-Opioid receptors protect from anoxic disruption of Na+ homeostasis via Na+ channel regulation. Cell Mol Life Sci 66:3505-16
Balboni, Gianfranco; Trapella, Claudio; Sasaki, Yusuke et al. (2009) Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore. J Med Chem 52:5556-9
Vergura, Raffaella; Balboni, Gianfranco; Spagnolo, Barbara et al. (2008) Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 29:93-103
Jinsmaa, Yunden; Marczak, Ewa D; Balboni, Gianfranco et al. (2008) Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph. Pharmacol Biochem Behav 90:651-7
Balboni, Gianfranco; Fiorini, Stella; Baldisserotto, Anna et al. (2008) Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem 51:5109-17
Koda, Yasuko; Del Borgo, Mark; Wessling, Susanne T et al. (2008) Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 16:6286-96
Salvadori, Severo; Fiorini, Stella; Trapella, Claudio et al. (2008) Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem 16:3032-8
Ryu, Eun Kyoung; Wu, Zhanhong; Chen, Kai et al. (2008) Synthesis of a potent and selective (18)F-labeled delta-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomography imaging. J Med Chem 51:1817-23

Showing the most recent 10 out of 48 publications